Recent News

By Category: Research

after Ebola outbreak in Uganda – Coastweek

Coastweekafter Ebola outbreak in UgandaCoastweekKAMPALA (Xinhua) — Uganda's ministry of health on Thursday announced 12 more people suspected of having the deadly Ebola hemorrhagic fever have been admitted in the mid-western Ugandan district of Kibaale, the epicenter of the outbreak.

August 3, 2012
| Filed under Research
Share

White powder scare shuts down hospital ER – KHOU

White powder scare shuts down hospital ERKHOUHOUSTON—It looked like a scene from a movie as the emergency room at Angelton Danbury Medical Center had to be shut down for several hours because of a possible anthrax scare. It all started when a Brazoria County resident received a package in the …and more »

August 3, 2012
| Filed under Research
Share

Test Results Show Unprecedented Achievement for Marburg Drug Candidate

(Benzinga) A new study testing a drug candidate to treat Marburg virus demonstrated significant survival rates up to four days after exposure to the disease. Referred to as AVI-7288, the drug is a post-exposure prophylactic targeting the Marburg virus which may cause hemorrhagic fever, a severe, life-threatening disease that exhibits fever and bleeding. The development Read More »

August 2, 2012
| Filed under Europe, North America, Agents & Toxins, Public Health, and Research
Share

Health teams face real-life horror in Ebola battle – NBCNews.com (blog)

Health teams face real-life horror in Ebola battleNBCNews.com (blog)The hemorrhagic virus is the stuff of real-life horror — spreading through contact with infected individuals, their bodily fluids and even clothing they have worn. In many cases Ebola leads to a rapid decline marked by fever, diarrhea, vomiting and …

August 2, 2012
| Filed under Research
Share

Test results show unprecedented achievement for Marburg drug candidate – MedCity News

Test results show unprecedented achievement for Marburg drug candidateMedCity NewsThrough its Hemorrhagic Fever Virus-Therapeutics Medical Countermeasures acquisition program (HFV-Tx MCM), JPM-TMT is targeting Marburg as a model for testing the development of rapidly adaptable platform-based, post-exposure therapeutics for all …and more »